hotspot -WSS

hotspot

author：entertainment 2025-09-29 12:30:21 - browse：44664

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Boston's new lab space is opening empty

WSS

EPA limits use of carcinogenic gas for sterilizing medical devices

Focused ultrasound for uterine fibroids: an uphill battle

Stigma and the return of syphilis

Lab trade group sues FDA to halt regulation of lab

Amid AI frenzy, a top HHS official's quest to create safeguards

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

focus

hotspot

entertainment

Apple is now the first public company to be valued at $3 trillion

Why scientists need input from humanists on sensitive research

Psychedelics group wrestles with new pharma identity

Addiction doctors spar with methadone clinics over legislation

Hollywood unions extend contract negotiations for actors

Addiction doctors spar with methadone clinics over legislation

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

As demand for Covid shots wanes, Moderna seeks its next success

Antibiotic resistance nearly killed me, so I'm raising awareness of it

focus

Ebola: Gilead Sciences antiviral shows promise as new treatment

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

David Sabatini, ex

Addiction doctors spar with methadone clinics over legislation

John Green on his newest strategy for fighting tuberculosis

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Wikipedia

hotspot

explore

hotspot